The accuracy of Vitek MS mass spectrometric identifications was assessed for 206 clinically significant isolates of aerobic Grampositive bacilli representing 20 genera and 38 species. The Vitek MS identifications were correct for 85% of the isolates (56.3% to the species level, 28.6% limited to the genus level), with misidentifications occurring for 7.3% of the isolates. I dentification of aerobic, Gram-positive bacilli (GPB) to the species level is challenging. Biochemical methods are slow and labor-intensive and may not provide reliable results. Molecular sequencing techniques have become the gold standard for identification of GPB (1-3) but are too expensive for routine use by the clinical microbiology laboratory. As a consequence, GPB identifications are often limited to the genus level or descriptive results (e.g., diphtheroid).
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Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) is a new technology offering accurate, fast, and affordable identification for bacteria and yeasts (4) (5) (6) (7) . Mass spectrometry results are graphed as peaks based on the mass/charge ratio of microbial proteins that have been ionized from intact cells obtained from pure culture. Identification is achieved by comparison of the mass spectral profile to a reference database.
The purpose of this study was to evaluate the accuracy of MALDI-TOF MS identifications generated by the Vitek MS system (v2.0; bioMérieux, Durham, NC) for aerobic GPB isolates commonly encountered in the clinical microbiology laboratory. The Vitek MS results were compared to identifications previously reported that were based on conventional biochemical or molecular methods. Sequencing of 16S rRNA or rpoB genes was performed to arbitrate discordant results. Although the Vitek MS system recently received FDA 510(k) de novo clearance, only a few of the species analyzed in this current study were included in the FDA clinical trials and data submission.
A total of 206 GPB isolates recovered from specimens submitted for culture from 31 December 2007 to 21 August 2012 were selected from the frozen stock database of the Cleveland Clinic Clinical Microbiology Laboratory for inclusion in the study. Duplicate isolates of the same species from a single patient were excluded. Approval was received by the institutional review board prior to initiation of the study. These clinical isolates had been previously identified using biochemical testing or molecular methods (sequencing of 16S rRNA or rpoB genes). The frozen isolates were plated on 5% sheep blood agar and incubated overnight at 35°C in 5% CO 2 . Isolates were subcultured a second time before Vitek MS testing was performed. The manufacturer's instructions were followed for Vitek MS testing.
A thin film of fresh colony growth was applied directly to the target slide. Each spot was covered with 1 l of matrix solution (␣-cyano-4-hydroxycinnamic acid; bioMérieux), allowed to dry, and analyzed on the Vitek MS instrument. If two attempts at direct colony testing failed to provide an acceptable single choice identification, an extraction method was employed. The on-slide extraction was performed by spotting the colony growth and then immediately adding 0.5 l 28.9% formic acid, drying, adding matrix, and drying prior to placement on the Vitek MS for analysis. Calibration of the mass spectrometer for every acquisition group was performed using Escherichia coli ATCC 8739. On each day of testing, one quality control organism (Staphylococcus aureus ATCC 29213, Enterobacter aerogenes ATCC 13048, Klebsiella oxytoca ATCC 13182, or Pseudomonas aeruginosa ATCC 10145) was tested.
The Vitek MS identifications (i.e., species level, genus level, or no result) were based on confidence level. Whenever the software provides identification with only one choice, an acceptable confidence value may range from 60 to 99.99 (8) . Two or more results with the same genus but multiple species were considered acceptable for genus identification only.
Isolates with a final Vitek MS identification that was discordant with the reference biochemical or molecular result previously determined at Cleveland Clinic were sent to bioMérieux, where sequencing of the 16S rRNA and rpoB genes was performed using previously published methods (9) (10) (11) . Sequencing data were analyzed using the GenBank database (12) and Bioinformatics Bacterial Identification (BIBI) software (13) . Final sequencing identifications were assigned according to Clinical and Laboratory Standards Institute (CLSI) interpretive criteria (14) .
The GPB isolates included in the study represented 20 genera and 38 species (Table 1) . After discrepancy testing, 96 of the 206 reference identifications were based on molecular testing. The Vitek MS result agreed with the reference method for 85% of the 206 isolates. Of the 175 correct identifications, 116 were correct to the species level and 59 were limited to the genus level. Vitek MS misidentifications occurred for 15 isolates (7.3%; Table 2 ). Vitek MS testing did not provide identifications for 16 isolates (7.8%).
The majority of isolates tested were from the genus Corynebacterium (n ϭ 121). Every Vitek MS identification was correct to the species level for 11 of 20 Corynebacterium species: Corynebacterium striatum (n ϭ 60 isolates), Corynebacterium jeikeium (n ϭ 10), Corynebacterium urealyticum (n ϭ 3), Corynebacterium coyleae (n ϭ 2), Corynebacterium simulans (n ϭ 2), Corynebacterium diphtheriae (n ϭ 1), Corynebacterium glucuronolyticum (n ϭ 1), Corynebacterium kroppenstedtii (n ϭ 1), Corynebacterium mastitidis (n ϭ 1), Corynebacterium pseudodiphtheriticum (n ϭ 1), Corynebacterium tuberculostearicum (n ϭ 1). Vitek MS identifications for all of the Corynebacterium amycolatum isolates (n ϭ 15) were split between multiple species (C. amycolatum/Corynebacte- were accurately identified to the species level if the accepted score was lowered from 2.0 to 1.7 (15) . In our study, 77% of the 114 Corynebacterium isolates with species-level reference identifications had accurate species-level Vitek MS results. The most difficult species for Vitek MS in this genus (C. afermentans) was also problematic for Bruker Biotyper, with unacceptable scores of 1.6 or less (15) . Species misidentification of two C. aurimucosum isolates as C. minutissimum occurred with Bruker (15), while the current Vitek MS study had the opposite situation (one C. minutissimum isolate misidentified as C. aurimucosum). The Bruker system required a preparatory extraction step to achieve a correct identification for most isolates (15) . In the current study, the final Vitek MS results for only three isolates (Bacillus species, Corynebacterium imitans, and Corynebacterium propinquum) were based on on-plate extraction. The other 203 Vitek MS results were generated with direct colony testing.
Konrad et al. reported accurate MALDI-TOF MS identification of 116 Corynebacterium species using Bruker Biotyper after ethanol and formic acid extraction, but most isolates were C. diphtheriae (n ϭ 78) (16) . The one C. diphtheriae isolate included in the current study was accurately identified by the Vitek MS.
Among the 32 Bacillus isolates tested in the current study, correct species Vitek MS identifications occurred for Bacillus pumilus (n ϭ 5 isolates), Bacillus licheniformis (n ϭ 3), and Bacillus megaterium (n ϭ 1). Twenty isolates in the Bacillus genus did not have a reference-level identification to the species level even though 16S or rpoB sequencing was performed on 15 of those isolates. Most of the Vitek MS Bacillus identifications were also at the genus level. The accuracy of six species identifications (Bacillus circulans [n ϭ Among the remaining GPB isolates, every Vitek MS identification was correct to the species level for Dermabacter hominis (n ϭ 5 isolates), Listeria monocytogenes (n ϭ 4), Brevibacterium casei (n ϭ 3), Trueperella bernardiae (n ϭ 2), Arcanobacterium haemolyticum (n ϭ 1), Gordonia bronchialis (n ϭ 1), and Weissella confusa (n ϭ 1). Species-level Vitek MS misidentifications occurred for the single Brevibacterium otitidis and Paenibacillus urinalis isolates tested (Table 2) . Seven genus-level misidentifications occurred with Vitek MS results of Paenibacillus durus that were actually Gordonia (n ϭ 2), Janibacter, Lysinibacillus, or Microbacterium species (n ϭ 3). One Microbacterium species isolate was misidentified by Vitek MS as Brevibacterium luteolum.
Although there are multiple published studies examining the research-use-only Bruker Biotyper system (15) (16) (17) , this is the first report describing identification of GPB other than Listeria monocytogenes and C. jeikeium with the FDA-cleared Vitek MS system. The percentage of isolates misidentified by Vitek MS in the current study was acceptably low (7.3% of isolates). Rejecting Vitek MS identifications of Paenibacillus durus and Lactobacillus species using the current database would prevent 60% of misidentifications observed in this study.
Identification of GPB by MALDI-TOF MS has the potential for significant clinical impact by providing more complete and prompt identifications (7) .
Some isolates with no Vitek MS result had unusual macroscopic characteristics (e.g., pinpoint size, stickiness, agar pitting, or excessive dryness), which made the target plate application challenging.
In conclusion, the Vitek MS provided accurate identification for most GPB commonly encountered by the clinical laboratory. Genus and species misidentifications occurred for 5.3% and 1.9% of isolates, respectively. The on-plate extraction step was required for only three isolates. Expansion of the database will further increase the usefulness of Vitek MS for identification of these challenging organisms.
